Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/27334
Title: Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain
Authors: Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.
Uludağ Üniversitesi/Veteriner Fakültesi/Patoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Hayvan Yetiştiriciliği, Beslenme ve Et Araştırma Enstitüsü.
0000-0002-3595-6286
Baǧdaş, Deniz
Çinkılıç, Nilüfer
Özbölük, Hasret Yücel
Özyiǧit, Musa Özgür
Gürün, Mine Sibel
AAR-6478-2021
AAG-8716-2019
AAH-5296-2021
AAH-2873-2021
15062425700
26533892300
55890590200
6507338060
55664349700
Keywords: Pharmacology & pharmacy
Antihyperalgesic
Chlorogenic acid
Chronic constrictive nerve injury
Neuropathic pain
Rat
Oxygen species ros
Inflammatory pain
Rat
Polyphenols
Issue Date: Oct-2013
Publisher: Springer
Citation: Bağdaş, D. vd. (2013). "Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain". Journal of Natural Medicines, 67(4), 698-704.
Abstract: Chlorogenic acid (CGA) is a natural organic phenolic compound that is found in many plants, fruits and vegetables. CGA has beneficial bioactivities and strong therapeutic effects in inflammatory processes. CGA-rich fractions have analgesic activity but CGA has not been tested previously in neuropathic pain, which results from tissue damage, inflammation or injury of the nervous system. Chronic constrictive nerve injury (CCI) is a peripheral neuropathic pain model which initiates an inflammatory cascade. We aimed to determine possible antihyperalgesic effects of CGA in neuropathic pain. Our study showed for the first time that CGA [50, 100 and 200 mg/kg; intraperitoneally (i.p.)] produced significant dose- and time-dependent antihyperalgesic activity in CCI-induced neuropathic pain. In addition, chronic administration of CGA (100 mg/kg/day; i.p. for 14 days) prevented the development of mechanical hyperalgesia and attenuated CCI-induced histopathological changes. On the other hand, CGA (200 mg/kg) did not affect falling latencies of rats in the rota rod test. Hence, CGA might represent a novel potential therapeutic option for the management of neuropathic pain.
URI: https://doi.org/10.1007/s11418-012-0726-z
https://link.springer.com/article/10.1007/s11418-012-0726-z
http://hdl.handle.net/11452/27334
ISSN: 1340-3443
1861-0293
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.